Literature DB >> 26377624

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases.

Ahmet Koluman1, Nejat Akar, İbrahim C Haznedaroğlu.   

Abstract

OBJECTIVE: Ankaferd hemostat (Ankaferd Blood Stopper®, ABS)-induced pharmacological modulation of essential erythroid proteins can cause vital erythroid aggregation via acting on fibrinogen gamma. Topical endoscopic ABS application is effective in the controlling of gastrointestinal (GI) system hemorrhages and/or infected GI wounds. Escherichia coli O157:H7, the predominant serotype of enterohemorrhagic E. coli, is a cause of both outbreaks and sporadic cases of hemorrhagic colitis. The aim of this study is to examine the effects of ABS on 6 different Shiga toxigenic E. coli serotypes including O26, O103, O104, O111, O145, and O157 and on other pathogens significant in foodborne diseases, such as Salmonella Typhimurium, Campylobacter jejuni, and Listeria monocytogenes, were also assessed.
MATERIALS AND METHODS: All strains were applied with different amounts of ABS and antimicrobial effect was screened. S. Typhimurium groups were screened for survival using the fluorescence in situ hybridization technique.
RESULTS: The relative efficacy of ABS solutions to achieve significant logarithmic reduction in foodborne pathogens E. coli O157:H7 and non-O157 serogroups and other emerging foodborne pathogens is demonstrated in this study. ABS has antibacterial effects.
CONCLUSION: Our present study indicated for the first time that ABS may act against E. coli O157:H7, which is a cause of thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and hemorrhagic colitis. The interrelationships between colitis, infection, and hemostasis within the context of ABS application should be further investigated in future studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26377624      PMCID: PMC5451695          DOI: 10.4274/tjh.2015.0073

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


  43 in total

Review 1.  Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat.

Authors:  Berat Z Haznedaroglu; Yavuz Beyazit; Sharon L Walker; Ibrahim C Haznedaroglu
Journal:  Crit Rev Oncol Hematol       Date:  2011-11-12       Impact factor: 6.312

2.  Antimicrobial activity of plant extract Ankaferd Blood Stopper.

Authors:  Nuriye Tasdelen Fisgin; Yeliz Tanriverdi Cayci; Ahmet Yilmaz Coban; Duzgun Ozatli; Esra Tanyel; Belma Durupinar; Necla Tulek
Journal:  Fitoterapia       Date:  2008-10-07       Impact factor: 2.882

3.  A new practical alternative for tumoural gastrointestinal bleeding: Ankaferd blood stopper.

Authors:  Ersan Ozaslan; Tugrul Purnak; Ayla Yildiz; Ibrahim C Haznedaroglu
Journal:  Dig Liver Dis       Date:  2009-12-11       Impact factor: 4.088

4.  The effect of Ankaferd blood stopper on severe radiation colitis.

Authors:  E Ozaslan; T Purnak; A Yildiz; T Akar; U Avcioglu; I C Haznedaroglu
Journal:  Endoscopy       Date:  2009-11-17       Impact factor: 10.093

5.  Ankaferd hemostat in the management of gastrointestinal hemorrhages.

Authors:  Yavuz Beyazit; Murat Kekilli; Ibrahim C Haznedaroglu; Ertugrul Kayacetin; Metin Basaranoglu
Journal:  World J Gastroenterol       Date:  2011-09-21       Impact factor: 5.742

6.  Effects of the topical hemostatic agent Ankaferd Blood Stopper on the incidence of alveolar osteitis after surgical removal of an impacted mandibular third molar.

Authors:  M Tek; I Akkas; O Toptas; F Ozan; I Sener; C Bereket
Journal:  Niger J Clin Pract       Date:  2014 Jan-Feb       Impact factor: 0.968

7.  Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability.

Authors:  Mevlut Kurt; Erkin Oztas; Sedef Kuran; Ibrahim K Onal; Murat Kekilli; Ibrahim C Haznedaroglu
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

8.  Effects of Ankaferd on anastomotic healing of colon.

Authors:  Gulden Cancan; Serkan Teksoz; Erman Aytac; Akif Enes Arikan; Hayriye Erman; Hafize Uzun; Ferhat Ozden; Ovgu Aydin; Murat Ozcan
Journal:  J Invest Surg       Date:  2013-08-29       Impact factor: 2.533

9.  Topical application of ankaferd hemostat in a patient with gastroduodenal amyloidosis complicated with gastrointestinal bleeding.

Authors:  Yavuz Beyazit; Fatih Oguz Onder; Serkan Torun; Adnan Tas; Tugrul Purnak; Ilyas Tenlik; Nesrin Turhan
Journal:  Blood Coagul Fibrinolysis       Date:  2013-10       Impact factor: 1.276

10.  Beneficial effects of Ankaferd Blood Stopper on dermal wound healing: an experimental study.

Authors:  Cagri Akalin; Serdar Kuru; Aziz Mutlu Barlas; Kemal Kismet; Bugra Kaptanoglu; Aydin Demir; Hesna Muzeyyen Astarci; Huseyin Ustun; Ertugrul Ertas
Journal:  Int Wound J       Date:  2012-09-03       Impact factor: 3.315

View more
  2 in total

Review 1.  Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Authors:  Cem Simsek; Sebnem Selek; Meltem Koca; Ibrahim Celal Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-07-27

2.  Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.

Authors:  Fatma Beyazit; Yavuz Beyazit; Alpaslan Tanoglu; Ibrahim C Haznedaroglu
Journal:  Med Hypotheses       Date:  2020-07-31       Impact factor: 1.538

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.